CD5L:p40, a novel heterodimeric regulator of type 2 inflammation.
Saved in:
| Title: | CD5L:p40, a novel heterodimeric regulator of type 2 inflammation. |
|---|---|
| Authors: | Wang C; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Immunology, University of Toronto, Toronto, ON, Canada., Zaghouani S; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Wallrapp A; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Newcomer K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States., Greenfield E; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Johnson JB; Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Immunology, University of Toronto, Toronto, ON, Canada., Barilla R; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Pawlak M; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Christian E; Broad Institute of MIT and Harvard, Cambridge, MA, United States., Burkett PR; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States., Leabo M; Celsius Therapeutics, Boston, MA, United States., Li P; Celsius Therapeutics, Boston, MA, United States., Soto H; BioLegend, San Diego, CA, United States., Chen RS; BioLegend, San Diego, CA, United States., Monell C; BioLegend, San Diego, CA, United States., Brown MH; Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom., Almo SC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, United States., Singer M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States., Regev A; Broad Institute of MIT and Harvard, Cambridge, MA, United States.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA, United States., Kuchroo VK; Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Mass General Hospital, and Harvard Medical School, Boston, MA, United States.; Broad Institute of MIT and Harvard, Cambridge, MA, United States. |
| Source: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2026 Mar 17; Vol. 215 (3). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association of Immunologists Country of Publication: England NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
